

# Jianchun Duan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7888995/publications.pdf>

Version: 2024-02-01

35  
papers

783  
citations

687363

13  
h-index

580821

25  
g-index

38  
all docs

38  
docs citations

38  
times ranked

1292  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combined Immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line Treatment of Driver-Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: An Updated Systematic Review and Network Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1655.	2.4	6
2	Establishment of prognostic nomograms for predicting the progression free survival of <sc>EGFR</sc>â€sensitizing mutation, advanced lung cancer patients treated with <sc>EGFRâ€TKIs</sc>. <i>Thoracic Cancer</i> , 2022, 13, 1289-1298.	1.9	1
3	Nab-PTX and nab-PTX combined with immune checkpoint inhibitors for relapsed small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8576-8576.	1.6	0
4	<i>PAPPA2</i> mutation as an indicator stratified patients benefit from immune checkpoint inhibitors in NSCLC and SKCM.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2617-2617.	1.6	0
5	Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 66-78.	1.9	32
6	The benefits of etoposide capsules as maintenance therapy for patients with extensive-stage small cell lung cancer: a prospective two-stage, two-center study. <i>Journal of Thoracic Disease</i> , 2021, 13, 343-352.	1.4	2
7	Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in nonâ€small cell lung cancers. <i>Science Advances</i> , 2021, 7, .	10.3	12
8	Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced NSCLC: A Systematic Review and Network Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1099-1117.	1.1	64
9	Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 2732-2739.	1.9	4
10	Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. <i>Lancet Oncology</i> , The, 2021, 22, 1265-1274.	10.7	102
11	Brigatinib treated <sc>ALK</sc> positive lung squamous cell carcinoma after failed chemotherapy: A case report. <i>Thoracic Cancer</i> , 2021, 12, 3273-3276.	1.9	3
12	Allele Frequencyâ€Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 556-567.	1.1	66
13	Complete response induced by antiâ€PDâ€1â€based immunotherapy with toripalimab in a patient with locally advanced lung adenocarcinoma who failed rapidly after concurrent chemoradiotherapy: A case report. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1511-1514.	1.5	2
14	Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Nonâ€Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2020, 3, e2013770.	5.9	34
15	ROS1 Fusion Mediates Immunogenicity by Upregulation of PD-L1 After the Activation of ROS1â€SHP2 Signaling Pathway in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 527750.	4.8	7
16	Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1857-1870.	1.1	19
17	A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients. <i>BMC Medicine</i> , 2020, 18, 232.	5.5	15
18	Retrospective analysis of the effectiveness and tolerability of nabâ€paclitaxel in Chinese elderly patients with advanced nonâ€smallâ€cell lung carcinoma. <i>Thoracic Cancer</i> , 2020, 11, 1149-1159.	1.9	8

#	ARTICLE	IF	CITATIONS
19	The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis. <i>Journal of Cancer</i> , 2020, 11, 3106-3113.	2.5	3
20	TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2020, 8, 146-154.	3.4	166
21	Recommendations of individualized medical treatment and common adverse events management for lung cancer patients during the outbreak of COVID-19 epidemic. <i>Thoracic Cancer</i> , 2020, 11, 1752-1757.	1.9	20
22	Pegylated recombinant human granulocyte colony-stimulating factor regulates the immune status of patients with small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 713-722.	1.9	3
23	Genomic and epigenomic profiles to distinguish pulmonary enteric adenocarcinoma from lung metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e13528-e13528.	1.6	0
24	Prognostic significance of molecular characteristics of cerebrospinal fluid for non-small cell lung cancer patients with leptomeningeal metastasis. <i>Thoracic Cancer</i> , 2019, 10, 1673-1682.	1.9	11
25	Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer. , 2019, 7, 198.		28
26	Hypoxia-inducible factor-1 $\alpha$ and nuclear factor- $\kappa$ B play important roles in regulating programmed cell death ligand 1 expression by epidermal growth factor receptor mutants in non-small cell lung cancer cells. <i>Cancer Science</i> , 2019, 110, 1665-1675.	3.9	50
27	Impact of PD-1, transforming growth factor- $\beta$ expression and tumor-infiltrating CD8 <sup>+</sup> T cells on clinical outcome of patients with advanced thymic epithelial tumors. <i>Thoracic Cancer</i> , 2018, 9, 1341-1353.	1.9	20
28	Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1166-1173.	1.9	10
29	Co-mutations of DNA damage response system as predictive biomarker for immune checkpoint blockades.. <i>Journal of Clinical Oncology</i> , 2018, 36, 3024-3024.	1.6	1
30	Associations between mutations of DNA damage response and prognosis in microsatellite instability prevalent tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, e24257-e24257.	1.6	0
31	The sharing of T cell clones in peripheral CD8+PD-1+ T cells with TILs is a novel biomarker predicting the efficacy of anti-PD-L1 therapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15007-e15007.	1.6	0
32	Phase I study of apatinib combined with docetaxel in EGFR-negative advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e21184-e21184.	1.6	0
33	Theoretical model and clinical validation of blood tumor mutation burden (bTMB) detection for cancer immunotherapy.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12034-12034.	1.6	0
34	Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1376-1387.	1.1	39
35	Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs). <i>Journal of Thoracic Oncology</i> , 2017, 12, 1766-1778.	1.1	51